Nanomedicine Market Size, Share & Analysis Report, 2023-2032
The global nanomedicine market size was exhibited at USD 180.66 billion in 2022 and is projected to hit around USD 551.16 billion by 2032, growing at a CAGR of 11.8% during the forecast period 2023 to 2032.
Key Pointers:
Nanomedicine Market Report Scope
|
Report Coverage |
Details |
|
Market Size in 2023 |
USD 201.98 Billion |
|
Market Size by 2032 |
USD 551.16 Billion |
|
Growth Rate from 2023 to 2032 |
CAGR of 11.8% |
|
Base year |
2022 |
|
Forecast period |
2023 to 2032 |
|
Segments covered |
Application, indication, molecule type, region |
|
Regional scope |
North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
|
Key companies profiled |
Abbott Laboratories; Combi Matrix Corporation; Celgene Corporation; Nano spectra Biosciences, Inc.;General Electric; Johnson & Johnson Services; Inc.; Mallinckrodt Pharmaceuticals;Merck & Co., Inc.;Pfizer, Inc.; Teva Pharmaceutical Industries Ltd.; Arrowhead Pharmaceuticals, Inc. |
Application Insights
The therapeutics segment is anticipated to witness a significant growth rate of 14.2%from 2023-2032, due to the existence of numerous products that fit into this category for the treatment of various ailments. These include medications, equipment, and drug delivery systems. Additionally, technological advancements facilitating the development of Nanotherapeutics that can cross biological barriers is anticipated to drive the nanomedicine market during the forecast period.
The drug delivery market contributed significantly to the overall market in 2021 as a result of rising rates of diseases including cancer and the COVID-19 virus as well as growing public awareness of the potential uses for nanomedicines. In addition, the effectiveness of nanotechnology in drug delivery will be attributed to improvement in reticule-endothelial system evasion, vivo dispersion, and favorable pharmacokinetics, thus, propelling the nanomedicine market growth.
Indication Insights
The clinical oncology segment dominated the nanomedicine market with revenue of USD 53.86 billionin 2022 and exhibits the fastest growth rate during the projected period. The increased prevalence of cancer disorders is attributed to the vast number of cancer treatment products now in the clinical stages of development as well as developments in the introduction of theranostic particles and devices. The method has the capacity to be used as a tool for both active and passive cancer targeting, thus, propelling market growth.
The need for developing more targeted cancer therapies is a key factor expected to drive R&D for clinical oncology. Nanomedicine is a rapidly evolving treatment modality owing to its targeting efficiency and fewer adverse effects in cancer treatment. Targeting a wide variety of cancers and tumors is considered as the major preclinical and clinical application of nanomedicine.
Molecule Type Insights
The nanoparticles segment held the highest share of 76.25% in 2022, accounting for the fastest growth rate throughout the forecast period. Due to the benefits that various nanoparticles offer, in addition to the growing usage of metal and metal oxide particles in photodynamic therapy (PDT) for the treatment of infectious diseases and cancer, product demand is raising, leading to significant market growth.
The use of nanoparticles in various healthcare settings is anticipated to spur expansion in the subsequent years. These molecules can carry out a variety of tasks owing to their capacity to bind to chemical moieties in the form of scaffolds. One of the key techniques of nanotechnology is the use of nanoparticles for selective binding by attaching them to ligands of cell receptors. Thus, it will drive market growth.
Regional Insights
North America dominated the regional market with a share of 48.58% in 2022. During the course of the forecast period, the region is expected to retain its leadership. This expansion can be ascribed to the existence of expanding alliances between businesses working in this area and nanomedicine start-up companies. Furthermore, the region's significant participation in the industrial sector is due to the support from governmental bodies combined with increased R&D expenditures.
The expansion of the market is driven by an increase in research funding and a rise in demand for life-threatening illness prophylaxis in the United States. The nation also boasts a sizable number of manufacturing firms with active strategic ventures in nanomedicine. To speed up the growth of its drug delivery development platform focused on nanoparticles to treat peripheral artery disease and other various applications, for instance, Advanced NanoTherapies raised $8.3 Million in Seed-Round Financing in October 2022.
In the upcoming years, the expansion of the nanomedicine market in Asia Pacific is anticipated to be significantly impacted by the increased public engagement in consensus conferences connected to nanoscience and nanotechnology. For instance, in August 2022 Beijing, China hosted the 9th International Conference on Nanoscience and Technology, China (China NANO 2022). The conference's goal is to disseminate scientific breakthroughs, developments in specific industry areas, technical advancements, new possibilities, and problems
Some of the prominent players in the Nanomedicine Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Nanomedicine market.
By Application
By Indication
By Molecule Type
By Region
Chapter 1 Research Methodology
1.1 Market Segmentation & Scope
1.1.1 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Nova one advisor Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity Flow Approach
1.6.1.2 Approach 2: Country-Wise Market Estimation Using Bottom-Up Approach
1.7 Global Market: Cagr Calculation
1.8 Research Assumptions
1.9 List Of Secondary Sources
1.10 List Of Primary Sources
1.11 Objectives
1.11.1 Objective 1
1.11.2 Objective 2
1.12 List of Abbreviations
Chapter 2 Market Definitions
Chapter 3 Executive Summary
3.1 Market Summary
Chapter 4 Global Nanomedicine Market Variables, Trends, & Scope
4.1 Nanomedicine Market Lineage Outlook
4.1.1 Parent Market Outlook
4.2 Penetration And Growth Prospect Mapping
4.3 Regulatory Framework
4.4 Market Driver Analysis
4.4.1 Rising Level Of Government Participation In R&D Funding
4.4.2 Introduction Of Technological Advancements In Diagnostic Procedures
4.4.3 Rising Usage Of Nanomedicine In Drug Delivery Technology
4.5 Market Restraint Analysis
4.5.1 Side Effects Associated With Intake Of Nanoparticles And Lower Adoption Rate By Patients
4.5.2 Hesitant Uptake By Medical And Pharmaceutical Industry
4.6 Porter’s Five Forces Analysis
4.7 SWOT Analysis
4.8 COVID-19 Impact Analysis
Chapter 5 Nanomedicine Market- Segment Analysis, by Application, 2020 - 2032
5.1 Global Nanomedicine Market: Application Movement Analysis
5.2 Therapeutics
5.2.1 Therapeutics Market Estimates And Forecast, 2020 - 2032
5.3 Active Implants
5.3.1 Active Implants Market Estimates And Forecast, 2020 - 2032
5.4 In-Vitro Diagnostics
5.4.1 In-Vitro Diagnostics Market Estimates And Forecast, 2020 - 2032
5.5 Drug Delivery
5.5.1 Drug Delivery Market Estimates And Forecast, 2020 - 2032
5.6 In-Vivo Imaging
5.6.1 In-Vivo Imaging Market Estimates And Forecast, 2020 - 2032
5.7 Implants
5.7.1 Implants Market Estimates And Forecast, 2020 - 2032
Chapter 6 Nanomedicine Market - Segment Analysis, by Indication, 2020 - 2032
6.1 Global Nanomedicine Market: Indication Movement Analysis
6.2 Clinical Oncology
6.2.1 Clinical Oncology Market Estimates And Forecast, 2020 - 2032
6.3 Infectious Diseases
6.3.1 Infectious Diseases Market Estimates And Forecast, 2020 - 2032
6.4 Clinical Cardiology
6.4.1 Clinical Cardiology Market Estimates And Forecast, 2020 - 2032
6.5 Orthopedics
6.5.1 Orthopedics Market Estimates And Forecast, 2020 - 2032
6.6 Others
6.6.1 Others Market Estimates And Forecast, 2020 - 2032
Chapter 7 Nanomedicine Market - Segment Analysis, By Molecule Type, 2020 - 2032
7.1 Nanomedicine Market: Molecule Type Movement Analysis
7.2 Nanoparticles
7.2.1 Nanoparticles Market Estimates And Forecast, 2020 - 2032
7.2.2 Metal & Metal Oxide Nanoparticles
7.2.2.1 metal & Metal Oxide NanoparticlesMarket Estimates And Forecast, 2020 - 2032
7.2.3 Liposomes
7.2.3.1 liposomes Market Estimates And Forecast, 2020 - 2032
7.2.4 Polymers & Polymer Drug Conjugates
7.2.4.1 Polymers & Polymer Drug Conjugates Market Estimates And Forecast, 2020 - 2032
7.2.5 Hydrogel Nanoparticles
7.2.5.1 Hydrogel Nanoparticles Market Estimates And Forecast, 2020 - 2032
7.2.6 Dendrimers
7.2.6.1 Dendrimers Market Estimates And Forecast, 2020 - 2032
7.2.7 Inorganic Nanoparticles
7.2.7.1 Inorganic Nanoparticles Market Estimates And Forecast, 2020 - 2032
7.3 Nanoshells
7.3.1 Nanoshells Market Estimates And Forecast, 2020 - 2032
7.4. Nano Tubes
7.4.1 Nanotubes Market Estimates And Forecast, 2020 - 2032
7.5 Nanodevices
7.5.1 Nanodevices Market Estimates And Forecast, 2020 - 2032
Chapter 8 Nanomedicine Market: - Segment Analysis, By Region, 2020 - 2032
8.1 nanomedicine Market: Regional Movement Analysis
8.2 north America
8.2.1 North America Market Estimates And Forecast, 2020 - 2032
8.2.2 U.S.
8.2.2.1 U.S. Market Estimates And Forecast, 2020 - 2032
8.2.3 Canada
8.2.3.1 Canada Market Estimates And Forecast, 2020 - 2032
8.3 Europe
8.3.1 Europe Market Estimates And Forecast, 2020 - 2032
8.3.2 U.K.
8.3.2.1 U.K. Market Estimates And Forecast, 2020 - 2032
8.3.3. Germany
8.3.3.1 Germany Market Estimates And Forecast, 2020 - 2032
8.3.4.France
8.3.4.1 France Market Estimates And Forecast, 2020 - 2032
8.3.5. Italy
8.3.5.1 Italy Market Estimates And Forecast, 2020 - 2032
8.3.6. Spain
8.3.6.1 Spain Market Estimates And Forecast, 2020 - 2032
8.4 Asia Pacific
8.4.1 Asia Pacific Market Estimates And Forecast, 2020 - 2032
8.4.2 Japan
8.4.2.1 Japan Market Estimates And Forecast, 2020 - 2032
8.4.3 China
8.4.3.1 China Market Estimates And Forecast, 2020 - 2032
8.4.4india
8.4.4.1 India Market Estimates And Forecast, 2020 - 2032
8.4.5 South Korea
8.4.5.1 South Korea Market Estimates And Forecast, 2020 - 2032
8.4.6 Australia
8.4.6.1 Australia Market estimates and forecast, 2020 - 2032
8.5 Latin America
8.5.1 Latin America Market Estimates And Forecast, 2020 - 2032
8.5.2 Brazil
8.5.2.1 Brazil Market Estimates And Forecast, 2020 - 2032
8.5.3 Mexico
8.5.3.1 Mexico Market Estimates And Forecast, 2020 - 2032
8.5.4 Argentina
8.5.4.1 Argentina Market estimates and forecast, 2020 - 2032
8.6 Middle East & Africa (MEA)
8.6.1 Middle East & Africa Market Estimates And Forecast, 2020 - 2032
8.6.2 South Africa
8.6.2.1 South Africa Market Estimates And Forecast, 2020 - 2032
8.6.3 Saudi Arabia
8.6.3.1 Saudi Arabia Market estimates and forecast, 2020 - 2032
8.6.4 UAE
8.6.4.1 UAE Market estimates and forecast, 2020 - 2032
Chapter 9 Competitive Landscape
9.1 Public Companies
9.1.1 Company Market Position Analysis
9.1.2 Competitive Dashboard Analysis
9.1.3 Strategic Framework
9.2 Private Companies
9.2.1 List Of Key Emerging Companies/Technology Disruptors/Innovators
9.2.2 Regional Network Map
9.3 Company Profiles
9.3.1 ABBOTT LABORATORIES
9.3.1.1 Company Overview
9.3.1.2 Financial Performance
9.3.1.3 Product Benchmarking
9.3.1.4 Strategic Initiatives
9.3.2 COMBIMATRIX CORPORATION
9.3.2.1 Company Overview
9.3.2.2 Financial Performance
9.3.2.3 Product Benchmarking
9.3.2.4 Strategic Initiatives
9.3.3 CELGENE CORPORATION
9.3.3.1 Company Overview
9.3.3.2 Financial Performance
9.3.3.3 Product Benchmarking
9.3.3.4 Strategic Initiatives
9.3.4 NANOSPECTRA BIOSCIENCES, INC.
9.3.4.1 Company Overview
9.3.4.2 Financial Performance
9.3.4.3 Product Benchmarking
9.3.4.4 Strategic Initiatives
9.3.5 GENERAL ELECTRIC
9.3.5.1 Company Overview
9.3.5.2 Financial Performance
9.3.5.3 Product Benchmarking
9.3.5.4 Strategic Initiatives
9.3.6 JOHNSON & JOHNSON SERVICES, INC.
9.3.6.1 Company Overview
9.3.6.2 Financial Performance
9.3.6.3 Product Benchmarking
9.3.6.4 Strategic Initiatives
9.3.7 MALLINCKRODT PHARMACEUTICALS
9.3.7.1 Company Overview
9.3.7.2 Financial Performance
9.3.7.3 Product Benchmarking
9.3.7.4 Strategic Initiatives
9.3.8 MERCK & CO., INC.
9.3.8.1 Company Overview
9.3.8.2 Financial Performance
9.3.8.3 Product Benchmarking
9.3.8.4 Strategic Initiatives
9.3.9 PFIZER, INC.
9.3.9.1 Company Overview
9.3.9.2 Financial Performance
9.3.9.3 Product Benchmarking
9.3.9.4 Strategic Initiatives
9.3.10 TEVA PHARMACEUTICAL INDUSTRIES LTD.
9.3.10.1 Company Overview
9.3.10.2 Financial Performance
9.3.10.3 Product Benchmarking
9.3.10.4 Strategic Initiatives
9.3.11 ARROWHEAD PHARMACEUTICALS, INC.
9.3.11.1 Company Overview
9.3.11.2 Financial Performance
9.3.11.3 Product Benchmarking
9.3.11.4 Strategic Initiatives
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers